Novavax
NVAX
230 hedge funds and large institutions have $1.06B invested in Novavax in 2024 Q2 according to their latest regulatory filings, with 59 funds opening new positions, 68 increasing their positions, 57 reducing their positions, and 29 closing their positions.
186% more capital invested
Capital invested by funds: $371M → $1.06B (+$690M)
103% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 29
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
19% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 57
14% more funds holding
Funds holding: 202 → 230 (+28)
4.55% more ownership
Funds ownership: 54.96% → 59.5% (+4.5%)
46% less call options, than puts
Call options by funds: $119M | Put options by funds: $221M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$62.5M |
| 2 |
BlackRock
New York
|
+$24.3M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
+$21.2M |
| 4 |
Jane Street
New York
|
+$18M |
| 5 |
SCM
Shah Capital Management
Raleigh,
North Carolina
|
+$15.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$109M |
| 2 |
Rafferty Asset Management
New York
|
-$14.3M |
| 3 |
Citigroup
New York
|
-$9.01M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$7.58M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$7.02M |
NVAX Hedge Fund Activity: Q2 2024 in Review
230 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q2 2024, worth a combined $1.06B — up 186% from $371M a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new NVAX positions and 29 closed out — a net gain of 30 holders — while 68 added to existing stakes and 57 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $62.5M. The largest seller was State Street, cutting an estimated $109M.
- 230 institutional investors held Novavax (NVAX) as of Q2 2024, up from 202 in Q1 2024.
- Funds reported $1.06B of Novavax stock for Q2 2024, up 186% quarter-over-quarter.
- 59 funds opened new Novavax positions in Q2 2024 and 29 closed out, a net change of +30 holders.
- The largest Novavax buyer in Q2 2024 was D.E. Shaw & Co, an estimated $62.5M added.
- The largest Novavax seller in Q2 2024 was State Street, an estimated $109M sold.
Based on aggregated 13F filings for Q2 2024.